Asterias Biotherapeutics (NYSEMKT:AST) : On Wednesday, The money flowed into the Asterias Biotherapeutics (NYSEMKT:AST) stock with an uptick to downtick ratio was recorded at 15.68. Transactions worth $0.03 million were done on upticks, confirming the buying interest in the stock. The outflow of money on downticks stood at $0 million. The total money flow into the stock was $0.03 million. The investors are using every small weakness in the stock to accumulate it, as can be seen in the $0.03 million of block transactions on upticks. The total money flow in block trades was $0.03 million. In terms of price action, Asterias Biotherapeutics (NYSEMKT:AST) traded down $0.02 during the session at $2.48. Compared to the previous days closing, the stock was down only by -0.8%. For the week, the stock is -12.68%, over previous weeks closing.
In an insider trading activity, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the CEO of Asterias Biotherapeutics, Inc., Cartt Stephen Lahue, had purchased 50,000 shares in a transaction dated on June 10, 2016. The transaction was executed at $2.93 per share with total amount equaling $146,500. Currently the company Insiders own 3.7% of Asterias Biotherapeutics shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by 115.44% . Institutional Investors own 10.3% of Asterias Biotherapeutics shares. During last six month period, the net percent change held by insiders has seen a change of 115.44%.
The company shares have dropped -40.48% from its 1 Year high price. On Sep 21, 2015, the shares registered one year high at $6.40 and the one year low was seen on Jan 20, 2016. The 50-Day Moving Average price is $3.11 and the 200 Day Moving Average price is recorded at $3.80. Asterias Biotherapeutics (NYSEMKT:AST): The stock opened at $2.42 on Wednesday but the bulls could not build on the opening and the stock topped out at $2.50 for the day. The stock traded down to $2.30 during the day, due to lack of any buying support eventually closed down at $2.35 with a loss of -6.00% for the day. The stock had closed at $2.50 on the previous day. The total traded volume was 237,121 shares.
Asterias Biotherapeutics, Inc. is a biotechnology company. The Company is focused in the field of regenerative medicine. It has three clinical stage product candidates: AST-OPC1 indicated for spinal cord injuries; AST-VAC2 indicated for lung cancer, and AST-VAC1 indicated for prostate cancer and acute myelogenous leukemia. The Companys product development is focused primarily on AST-OPC1 and AST-VAC2. The Companys lead therapeutic program focuses on the development of AST-OPC1 for spinal cord injury. AST-OPC1 product consists of glial progenitor cells, which are cells that become glial cells after injection. AST-VAC1 is an autologous product (using cells that come from the treated patient) consisting of mature antigen-presenting dendritic cells pulsed with ribonucleic acid (RNA) for the protein component of human telomerase (hTERT) and a portion of a lysosomal targeting signal (LAMP).